PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment: a Single-arm, Phase II Clinical Study
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Adebrelimab (Primary) ; Ipilimumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
Most Recent Events
- 16 Apr 2025 Planned End Date changed from 1 Sep 2024 to 30 Sep 2025.
- 16 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2023 New trial record